Abstract
Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki University Hospital. They were treated with YNK-01, a prodrug of cytarabine for oral administration. YNK-01 was given for 2 weeks and repeated every 4 weeks for as long as possible. There were 13 patients with NC, 10 with PD, and no PR. Among NC cases, 5 patients were maintained with NC for longer than 6 months. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc), but no severe side effects over Grade 3 were observed.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
English Abstract
-
Multicenter Study
MeSH terms
-
Administration, Oral
-
Aged
-
Anemia / chemically induced
-
Anorexia / chemically induced
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Arabinonucleotides / administration & dosage
-
Arabinonucleotides / adverse effects
-
Arabinonucleotides / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Cytidine Monophosphate / administration & dosage
-
Cytidine Monophosphate / adverse effects
-
Cytidine Monophosphate / analogs & derivatives*
-
Cytidine Monophosphate / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukopenia / chemically induced
-
Liver Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Thrombocytopenia / chemically induced
Substances
-
Antineoplastic Agents
-
Arabinonucleotides
-
1-arabinofuranosylcytosine-5'-stearylphosphate
-
Cytidine Monophosphate